Mabpharm Limited (HKG:2181)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
0.5500
-0.0100 (-1.79%)
At close: Mar 27, 2026
Market Cap2.27B -8.3%
Revenue (ttm)718.98M +150.2%
Net Income63.58M
EPS0.01
Shares Out4.12B
PE Ratio49.42
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,197,000
Average Volume3,431,150
Open0.5900
Previous Close0.5600
Day's Range0.5500 - 0.6000
52-Week Range0.4000 - 0.9400
Beta0.94
RSI52.56
Earnings DateMar 26, 2026

About Mabpharm

Mabpharm Limited, a biopharmaceutical company, engages in research, development, production, and commercialization of drugs and biosimilar for cancers and autoimmune diseases in the People’s Republic of China. The company offers CMAB007, a recombinant humanized anti-immunoglobulin E monoclonal antibody for treatment of asthma patients; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the first-line treatment of metastatic colorectal cancer; and CMAB008, a recombinant anti-TNF-alpha chimeric monoclonal antibody for the treatment... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 383
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2181
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements